• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体肿瘤发生-对治疗的影响。

Pituitary Tumorigenesis-Implications for Management.

机构信息

Endocrinology and Diabetes Clinic, University Hospital of Heraklion, School of Medicine, University of Crete, 71500 Crete, Greece.

出版信息

Medicina (Kaunas). 2023 Apr 21;59(4):812. doi: 10.3390/medicina59040812.

DOI:10.3390/medicina59040812
PMID:37109772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10145673/
Abstract

Pituitary neuroendocrine tumors (PitNETs), the third most common intracranial tumor, are mostly benign. However, some of them may display a more aggressive behavior, invading into the surrounding structures. While they may rarely metastasize, they may resist different treatment modalities. Several major advances in molecular biology in the past few years led to the discovery of the possible mechanisms involved in pituitary tumorigenesis with a possible therapeutic implication. The mutations in the different proteins involved in the Gsa/protein kinase A/c AMP signaling pathway are well-known and are responsible for many PitNETS, such as somatotropinomas and, in the context of syndromes, as the McCune-Albright syndrome, Carney complex, familiar isolated pituitary adenoma (FIPA), and X-linked acrogigantism (XLAG). The other pathways involved are the MAPK/ERK, PI3K/Akt, Wnt, and the most recently studied HIPPO pathways. Moreover, the mutations in several other tumor suppressor genes, such as and , are responsible for the MEN1 and MEN4 syndromes and succinate dehydrogenase (SDHx) in the context of the 3PAs syndrome. Furthermore, the pituitary stem cells and miRNAs hold an essential role in pituitary tumorigenesis and may represent new molecular targets for their diagnosis and treatment. This review aims to summarize the different cell signaling pathways and genes involved in pituitary tumorigenesis in an attempt to clarify their implications for diagnosis and management.

摘要

垂体神经内分泌肿瘤(PitNETs)是第三常见的颅内肿瘤,大多为良性。然而,其中一些可能表现出更具侵袭性的行为,侵犯周围结构。尽管它们很少转移,但可能对不同的治疗方式产生抵抗。过去几年分子生物学的几项重大进展导致发现了可能涉及垂体肿瘤发生的潜在机制,并具有可能的治疗意义。涉及 Gsa/蛋白激酶 A/cAMP 信号通路的不同蛋白的突变是众所周知的,它们与许多 PitNETs 有关,如生长激素瘤,并且在综合征的背景下,如 McCune-Albright 综合征、Carney 综合征、家族性孤立性垂体腺瘤(FIPA)和 X 连锁肢端巨大症(XLAG)。涉及的其他途径是 MAPK/ERK、PI3K/Akt、Wnt,以及最近研究的 HIPPO 途径。此外,几种其他肿瘤抑制基因的突变,如 和 ,与 MEN1 和 MEN4 综合征以及 3PAs 综合征中的琥珀酸脱氢酶(SDHx)有关。此外,垂体干细胞和 miRNAs 在垂体肿瘤发生中起着至关重要的作用,可能成为其诊断和治疗的新分子靶点。本综述旨在总结涉及垂体肿瘤发生的不同细胞信号通路和基因,试图阐明它们对诊断和管理的意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa3/10145673/818062151d6f/medicina-59-00812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa3/10145673/7986dc3f885c/medicina-59-00812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa3/10145673/818062151d6f/medicina-59-00812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa3/10145673/7986dc3f885c/medicina-59-00812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fa3/10145673/818062151d6f/medicina-59-00812-g002.jpg

相似文献

1
Pituitary Tumorigenesis-Implications for Management.垂体肿瘤发生-对治疗的影响。
Medicina (Kaunas). 2023 Apr 21;59(4):812. doi: 10.3390/medicina59040812.
2
Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond.垂体肿瘤发生机制的见解:从桑格测序到新一代测序及其他。
Expert Rev Endocrinol Metab. 2019 Nov;14(6):399-418. doi: 10.1080/17446651.2019.1689120. Epub 2019 Dec 2.
3
Familial pituitary tumors.家族性垂体瘤
Handb Clin Neurol. 2014;124:339-60. doi: 10.1016/B978-0-444-59602-4.00023-X.
4
The Spectrum of Familial Pituitary Neuroendocrine Tumors.家族性垂体神经内分泌肿瘤谱系
Endocr Pathol. 2023 Mar;34(1):57-78. doi: 10.1007/s12022-022-09742-0. Epub 2022 Nov 18.
5
Update on the Genetics of Pituitary Tumors.垂体瘤遗传学研究进展。
Endocrinol Metab Clin North Am. 2020 Sep;49(3):433-452. doi: 10.1016/j.ecl.2020.05.005.
6
Genetic Aspects of Pituitary Adenomas.垂体腺瘤的遗传学方面。
Endocrinol Metab Clin North Am. 2017 Jun;46(2):335-374. doi: 10.1016/j.ecl.2017.01.004. Epub 2017 Mar 18.
7
Genetic factors in the development of pituitary adenomas.垂体腺瘤发生发展中的遗传因素。
Endocr Dev. 2010;17:121-133. doi: 10.1159/000262534. Epub 2009 Nov 24.
8
Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects.导致垂体肿瘤的种系和嵌合体突变:遗传和分子方面。
J Endocrinol. 2019 Feb 1;240(2):R21-R45. doi: 10.1530/JOE-18-0446.
9
The pathophysiology of pituitary adenomas.垂体腺瘤的病理生理学。
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):525-41. doi: 10.1016/j.beem.2009.05.004.
10
Molecular genetic advances in pituitary tumor development.垂体肿瘤发生发展中的分子遗传学进展。
Expert Rev Endocrinol Metab. 2015 Jan;10(1):35-53. doi: 10.1586/17446651.2015.955795. Epub 2014 Sep 2.

引用本文的文献

1
"Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis".他莫昔芬用于残留的神经内分泌垂体肿瘤:一项整合受体分析、试点试验和靶标通路分析的概念验证研究
Endocrine. 2025 Sep 1. doi: 10.1007/s12020-025-04404-7.
2
Liquid Biopsy in Pituitary Neuroendocrine Tumors-Potential Biomarkers for Diagnosis, Prognosis, and Therapy.垂体神经内分泌肿瘤中的液体活检——用于诊断、预后和治疗的潜在生物标志物
Int J Mol Sci. 2025 Apr 25;26(9):4058. doi: 10.3390/ijms26094058.
3
[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].

本文引用的文献

1
Treatment of Prolactinoma.催乳素瘤的治疗。
Medicina (Kaunas). 2022 Aug 13;58(8):1095. doi: 10.3390/medicina58081095.
2
β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.β-连环蛋白在人类泌乳素细胞瘤细胞的膜中减少,并且它在泌乳素分泌肿瘤模型中被替莫唑胺抑制。
Tumour Biol. 2022;44(1):85-105. doi: 10.3233/TUB-211500.
3
Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.新辅助 BRAF 和 MEK 抑制剂靶向治疗成人颅咽管瘤:一种新的治疗模式。
[垂体神经内分泌肿瘤患者病理形态学检查的统一。新分类的争议问题]
Probl Endokrinol (Mosk). 2023 Nov 14;70(3):31-45. doi: 10.14341/probl13376.
Front Endocrinol (Lausanne). 2022 Jun 9;13:882381. doi: 10.3389/fendo.2022.882381. eCollection 2022.
4
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.USP8 突变的促肾上腺皮质激素细胞瘤体外对帕瑞肽反应改善。
Endocr Relat Cancer. 2022 Jun 29;29(8):503-511. doi: 10.1530/ERC-22-0088. Print 2022 Aug 1.
5
P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.P720R USP8突变与促肾上腺皮质激素分泌性垂体神经内分泌肿瘤对帕瑞肽的更好反应相关。
Cancers (Basel). 2022 May 16;14(10):2455. doi: 10.3390/cancers14102455.
6
Circulating Noncoding RNAs in Pituitary Neuroendocrine Tumors-Two Sides of the Same Coin.循环非编码 RNA 在垂体神经内分泌肿瘤中的作用——同一事物的两个方面。
Int J Mol Sci. 2022 May 4;23(9):5122. doi: 10.3390/ijms23095122.
7
Targeted therapies in the medical management of craniopharyngioma.颅咽管瘤的医学治疗中的靶向治疗。
Pituitary. 2022 Jun;25(3):383-392. doi: 10.1007/s11102-022-01212-4. Epub 2022 Mar 17.
8
Overview of the 2022 WHO Classification of Pituitary Tumors.《2022 年世卫组织垂体肿瘤分类概述》。
Endocr Pathol. 2022 Mar;33(1):6-26. doi: 10.1007/s12022-022-09703-7. Epub 2022 Mar 15.
9
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.急性髓系白血病特定基因组异常的新兴靶向治疗。
Int J Mol Sci. 2022 Feb 21;23(4):2362. doi: 10.3390/ijms23042362.
10
Diagnosis and Treatment of Acromegaly: An Update.肢端肥大症的诊断与治疗:最新进展。
Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007.